BACKGROUND: Immunoglobulin (Ig)G replacement with intravenous or subcutaneous immunoglobulins is a lifelong substitutive therapy in @entity1 with @entity465 ( @entity465 ). @entity2142 after immunoglobulin therapy was described in @entity1 receiving high immunoglobulin dosages. The issue of @entity2142 after immunoglobulin administration at replacement doses has been considered of little clinical significance. STUDY DESIGN AND METHODS: This was a single-center observational study over a 2-year period on immunoglobulin-induced @entity2142 in a cohort of 162 @entity1 with @entity465 treated with immunoglobulin administered at replacement dosages. RESULTS: Six @entity1 had signs and symptoms of immunoglobulin-induced @entity2142 . Two additional asymptomatic @entity1 were identified by a short-term study run on 16 randomly selected asymptomatic @entity1 . Alloantibodies eluted from @entity1 ' red blood cells (RBCs) had anti-A and Rh specificities (anti-D and anti-C). The immunoglobulins contained alloantibodies with the same specificities of the antibodies eluted from @entity1 ' RBCs. CONCLUSION: @entity2142 occurred in @entity1 receiving immunoglobulin at replacement dosages. Polyvalent immunoglobulin preparations contained multiple clinically significant antibodies that could have unexpected hemolytic consequences, as anti-C whose research and titration are not required by the European Pharmacopoeia. The issue of @entity2142 in long-term recipients of immunoglobulin treatment administered at replacement dosages should be more widely recognized.

@entity2142 in patients with XXXX on immunoglobulin replacement treatment.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity465 :: ('MESH:D007153', 'Disease') :: ['primary antibody deficiencies', 'PADs'] @entity2142 :: ('MESH:D006461', 'Disease') :: ['hemolysis', 'Hemolysis']
@entity465 :: (MESH:D007153,Disease) :: ['antibody deficiencies']
